Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that block EGFR.

The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer ...

TA-MUC1, the target of gatipotuzumab ... for datopotamab deruxtecan (Dato-DXd), an ADC targeting EGFR-mutated non–small cell lung cancer (NSCLC) developed by Daiichi Sankyo and AstraZeneca.